Molins de Rei, Spain

Ferran Pons Lambiez

This inventor holds 1 USPTO granted patent. Top assignee: Lipotec, S.a.. Active years: 2006.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ferran Pons Lambiez. Retrieved from https://idiyas.com/inventor/ferran-pons-lambiez

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2006

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ferran Pons Lambiez: Innovator in Anticancer Drug Delivery

Introduction

Ferran Pons Lambiez is a notable inventor based in Molins de Rei, Spain. He has made significant contributions to the field of medical technology, particularly in the development of innovative drug delivery systems for cancer treatment. His work focuses on enhancing the efficacy of anticancer drugs through advanced encapsulation techniques.

Latest Patents

Ferran holds a patent for "Liposomes encapsulating anticancer drugs and use thereof in the treatment of malignant tumors." This invention involves liposomes that are coated with a lipopeptide composed of three substructures: a lipid fragment, an active oligopeptide, and an oligopeptide spacer. This innovative approach allows for intravenous administration of anticancer drugs, targeting malignant tumors more effectively.

Career Highlights

Ferran Pons Lambiez is currently associated with Lipotec, S.A., where he continues to advance his research in drug delivery systems. His work has the potential to significantly improve treatment outcomes for patients suffering from various forms of cancer.

Collaborations

Ferran collaborates with esteemed colleagues, including Francesca Reig Isart and Angels Fabra Fres. Their combined expertise contributes to the ongoing development of cutting-edge solutions in the field of oncology.

Conclusion

Ferran Pons Lambiez is a pioneering inventor whose work in liposomal drug delivery systems represents a significant advancement in cancer treatment. His innovative approach has the potential to change the landscape of how malignant tumors are treated, offering hope to many patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…